title: Low-dose clozapine improves dyskinesias in Parkinson's disease.
abstract: The severity of parkinsonian motor disability and dyskinesias was evaluated in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist apomorphine, before and after low-dose clozapine (50 mg) for 18 +/- 2 days. There was a significant 59% improvement (p < 0.05) of apomorphine-induced dyskinesias without aggravation of parkinsonian motor disability following clozapine treatment. The results suggest that low-dose clozapine, already shown to improve psychotic symptoms, may help to reduce severe levodopa-induced dyskinesias in parkinsonian patients.
authors.affiliation: Department of Neurology, Fontmaure Hospital, Clermont-Ferrand, INSERM U 289, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Durif
authors.forename: M
authors.initials: M
authors.lastname: Vidailhet
authors.forename: F
authors.initials: F
authors.lastname: Assal
authors.forename: C
authors.initials: C
authors.lastname: Roche
authors.forename: A M
authors.initials: AM
authors.lastname: Bonnet
authors.forename: Y
authors.initials: Y
authors.lastname: Agid
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D003024:Clozapine / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged; D009069:Movement Disorders / Q000517:prevention & control*; D010300:Parkinson Disease / Q000188:drug therapy*; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine